Breast conservation after neoadjuvant therapy for tumors ≥5 cm: A prospective cohort study  by Libson, Shai et al.
Research Paper
Breast conservation after neoadjuvant therapy for tumors ≥5 cm:
A prospective cohort study
Shai Libson a,*, Vadim Koshenkov a, Steven Rodgers a, Judith Hurley b, Eli Avisar a
a Department of Surgery, Miller School of Medicine, University of Miami, Miami, USA
b Department of Medicine, Miller School of Medicine, University of Miami, Miami, USA
A R T I C L E I N F O
Article history:
Received 7 October 2015
Received in revised form 14 December
2015
Accepted 16 December 2015
Available online 6 January 2016
Keywords:
Breast cancer
Breast conservation
Neoadjuvant therapy
A B S T R A C T
Introduction: Neoadjuvant therapy (NT) can facilitate breast conservation (BC). Similar oncologic out-
comes have been reported with BC and mastectomy for T1 and T2 lesions, but studies of BC results for
tumors ≥5 cm are limited. Our experience with BC for tumors ≥5 cm is reported.
Patients and methods: A retrospective analysis of a prospectively collected database of all breast cancer
patients treated with NT at our institution between 2003 and 2010 was performed to identify patients
treated with BC for tumors ≥5 cm. Demographics, stage, tumor histology, pathologic response, tumor
margins, failure patterns and rates, as well as survival rates were recorded.
Results: Thirty patients treated with BC after NT for large tumors were identiﬁed. The only selection
criteria for BC were technical ability with acceptable cosmetic results and negative margins. Patients with
genetic predisposition for additional breast cancer were excluded. The mean follow-up was 43 months
and the mean age at diagnosis was 51. The mean tumor size at diagnosis was 6.4 cm and the mean patho-
logical size was 2.1 cm. Four of thirty (13.3%) had either systemic progression or regional recurrence. Three
patients had systemic progression, 2 had regional recurrence and none had local recurrence. At a mean
follow-up of 43 months, the success rate of BC on intent to treat basis was 96.7%, with an overall sur-
vival of 86.7% and disease-free survival of 83.3%.
Conclusion: BC after NT is a safe option for carefully selected patients with tumors ≥5 cm. In this series,
the oncologic results for the duration of the study were comparable to those reported after mastectomy.
© 2015 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Multiple prospective randomized trials [1], some with a follow-
up of 20 years, have established equivalent survival rates between
breast conservation (BC) with negative margins and mastectomy.
The EBCTCGmeta-analysis [2] further demonstrated improved overall
survival with the addition of radiation to surgery. Neoadjuvant
therapy (NT) has become a common approach for management of
locally advanced breast cancer. The theoretical advantage of this strat-
egy is threefold: an earlier systemic therapy targeting micro
metastases, the ability to assess tumor response in vivo and the pos-
sible downsizing of the tumor enabling BC.
The use of BC for larger tumors downsized by NT presents some
concerns regarding the adequacy of the resection and the possi-
bility of a piecemeal tumor response resulting in residual satellite
nodules in the ﬁeld of the original tumor. The data for T3 tumors
are limited because such large tumor sizes at presentation are rare
nowadays. In fact NSABP B-18 had only 13% of patients with T3
tumors [3] and NSABPB-27 had 29% of such patients [4]. Further-
more those patients are usually offered a mastectomy and little
consideration is given to BC. In our institution we treat a relative-
ly large percentage of patients presenting with locally advanced
tumors. We sought to investigate the feasibility of BC in this very
speciﬁc group of patients. The aim of this study was to report the
survival rates and failure patterns for tumors ≥5 cm treated by BC
after NT at our institution.
2. Patients and methods
After appropriate institutional IRB approval, a retrospective anal-
ysis of a prospectively collected database of all breast cancer patients
treated with NT at our institution between 2003 and 2010 was per-
formed to identify patients treated with BC for tumors ≥5 cm, not
including T4 disease. All patients received NT, which consisted of
either hormonal or chemotherapy treatments. At our institution pa-
tients with advanced locoregional and no systemic disease are usually
offered NT; these include patients with tumors ≥5 cm. The deci-
sion for BC was made by the surgeon and the patient’s preference,
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as well as surgical feasibility based on breast size, tumor location
and residual tumor volume according to previously published prin-
ciples [5]. A second attempt for breast conservation was done if
positive margins were obtained, If not feasible completion mas-
tectomy was performed. Advanced oncoplastic techniques and
contralateral breast reduction were done when deemed necessary
for cosmetic reasons. We refer to BC combined with bilateral breast
reductions as an “oncoreductive procedure.” Tumor size was as-
sessed at presentation by mammography and ultrasound, and
response to NT was characterized according to the RECIST criteria
by measuring pathological size [6]. Tumor stage, histology grade,
and receptor status were recorded and were available in the vast
majority of the cases. Local, regional and systemic failure patterns
were recorded during the follow-up interval. Qualitative and quan-
titative variables were analyzed by chi square and Student t test,
respectively; P < 0.05 was considered signiﬁcant. The work has been
reported in line with the STROBE criteria [7].
3. Results
Two hundred ninety patients received NT, of whom 84 had
tumors ≥5 cm and were not classiﬁed as T4. Fifty-four patients were
not offered breast conservation because of patient preference, genetic
predisposition for breast cancer, or because of surgical and onco-
logic inability. Thirty patients treated with breast conservation after
NT make up the main study group. The average follow-up interval
was 43 months and the mean age at diagnosis was 51 years. Tumor
histology was ductal in 24/30 (80%) patients and lobular in 6/30
(20%). NT consisted of chemotherapy for 25/30 (83.3%) patients
(23/25 ductal and 2/24 lobular) and hormonal therapy for 5/30
(16.7%) patients (1/5 ductal and 4/5 lobular). The mean tumor size
at diagnosis was 6.4 cm. Estrogen receptors (ER) were positive in
17/30 (56.7%) patients and Her2 was ampliﬁed in 10/30 (33.3%) pa-
tients. Low grade was found in 6 (20%) patients, intermediate grade
in 11 patients (37%) and high grade in 13 (43%) patients. Twenty
four had an axillary dissection, 5 had SLNB and in 1 patient no ax-
illary staging was done due to old age at diagnosis.
Negative margins were obtained at the ﬁrst attempt in 28 pa-
tients and on the second attempts in one patient. One patient
underwent a completion mastectomy for grossly positive margins.
Eight patients underwent an oncoreductive procedure. The mean
pathological size at the time of resection was 2.1 cm, and 6/30 (20%)
patients had pCR in the breast and lymph nodes. Thirteen out of
thirty (43.3%) patients had a complete clinical response, 8/30 (26.7%)
had partial response and 9/30 (30%) had stable disease. Table 1 sum-
marizes the characteristics of the study group. Patients undergoing
mastectomy had statistically larger tumors at presentation and lower
rates of HER2 ampliﬁed tumors.
Postoperative treatment consisted of radiation therapy to all but
one patient who did not receive therapy due to old age at diagno-
sis. Adjuvant hormonal therapy was given to all ER positive patients,
and one patient discontinued therapy. All Her-2 positive patients
received trastuzumab.
Overall, at 43 months of follow-up, the success rate of BC on
intent to treat basis was 96.7%. The disease-free survival was 83.3%
and the overall survival was 86.7%, with four patients dying during
the follow-up interval, 3 frommetastatic disease and one from un-
related causes. The fourth patient was diagnosed at the age of 91
and had no evidence of disease at the time of death.
Local, regional and systemic failures, as well as breast cancer mor-
tality and overall mortality, were compared between the BC and the
mastectomy groups and are summarized in Table 2. There were no
statistically signiﬁcant differences in any of those parameters. In the
BC group, three patients (10%) developed systemic progression, of
whom one had concomitant regional recurrence. An additional
patient had isolated regional recurrence for a total of 2/30 (6.7%)
regional recurrence. No in breast local failure occurred. All pa-
tients with systemic progression or recurrence did not reach
complete response to NT. In more details, one patient with posi-
tive margins whowas treated by completionmastectomy developed
regional recurrence 18 months after diagnosis and died 10 months
following regional recurrence. The second patient developed bone
metastasis 32 months after diagnosis and died 18 months follow-
ing the systemic progression. The third patient developed bone, liver
and lung metastasis 44 months after diagnosis and died 6 months
following the systemic progression. The fourth patient developed
regional recurrence in the axilla 44 months after diagnosis and was
treated with local excision.
In comparison 9/54 patients treated with mastectomy had sys-
temic failure (16.7%), 2 with concurrent regional failures (3.7%), and
there were no local failures.
Similarly, 9/54 (16.7%) patients in the mastectomy group died
from all causes, of which 5 (9.3%) were breast cancer deaths.
4. Discussion
NT is increasingly used for locoregional advanced disease. With
the adoption of complex oncoplastic techniques, including
oncoreductive procedures, patients with larger residual tumors fol-
lowing NT are candidates for BC. Our aimwas to study a very speciﬁc
group of patients presenting with very large tumors of ≥5 cm. This
Table 1
Clinical characteristics.
Breast
conservation
Mastectomy P value
Age
Mean 51.4 52.9 Not signiﬁcant (NS)
<50 17 (57) 22 (41)
≥50 13 (43) 32 (59)
Histology
Ductal 24 (80) 38 (70) NS
Lobular 6 (20) 16 (20)
No data 0 2
ER positive 17 (57) 33 (63) NS
Her2 positive 10 (33) 5 (4) 0.014
Grade
I 6 (20) 6 (11) NS
II 11 (37) 21 (39)
III 13 (43) 27 (50)
Clinical size
Mean 6.4 7.2 0.027
NT
Chemotherapy 25 (83) 51 (95) NS
Hormonal 5 (17) 3 (5)
Pathological size
Mean 2.2 2.5 NS
Pathological nodal statusa
N0/N1 22 (76) 40 (74) NS
N2/N3 7 (24) 14 (26)
Response
Complete response 13 (43) 18 (33) NS
Partial response 8 (27) 19 (35)
No response 9 (30) 17 (32)
a In 1 patient no axillary staging was done due to old age at diagnosis.
Table 2
Failure pattern and outcome at mean follow-up of 43 months.
Breast conservation Mastectomy P value
Failure pattern n = 30 n = 54
Systemic 3/30 (10) 9/54 (18.5) NS
Regional 2/30 (6.7) 2/54 (5.5)
Local 0 0
Breast cancer-speciﬁc death 3/30 (10) 5/54 (9.3) NS
Death 4/30 (13.3) 9/54 (16.7)
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speciﬁc subgroup has been largely under-represented in previous
studies [3,4]. Our study includes 83 patients with tumors ≥5 cm that
were not T4 tumors, of which 30 (36%) had BCT.
There are three main aspects to the evaluation of BC after NT
for patients who were not surgical candidates at all or were can-
didates for a mastectomy only prior to NT. The ﬁrst aspect is the
success rate of BC or the ability to perform the surgery and obtain
a clear margin, which is inﬂuenced partly by the response to NT.
The success rate ramiﬁes into the immediate success rate and the
long-term success rate in conserving the breast. The complete clin-
ical response and pCR rates are not statistically higher than published
by others [3]. As can be seen in our results the immediate success
rate was 96.7%; these results are not inferior to previously pub-
lished data where the positive margins rate may be as low as 12.4%
[8], and the reported short-term completion mastectomy rate, 14%
[9]. The overall 5-year local failure rates after BC and radiation vary
between 6.7% for node negative disease and 11% for node positive
disease [2].
The second aspect is the disease-free survival, disease-speciﬁc
survival and the overall survival when compared to mastectomy pa-
tients with the same stage of disease at presentation. These rates
are not inferior to the results of the patients undergoing mastec-
tomy in our study.
Different from other publications we did not mandate shrink-
age below a speciﬁc tumor size after NT or a speciﬁc histology in
order to be eligible for BC. Our series included 6 patients with lobular
carcinoma, 6 patients treated with hormonal NT and a mean ypT
of 2.1 cm. Only the technical ability of breast conserving surgery with
acceptable cosmetics and negative margins dictated the eligibili-
ty. That requirement does take into account also the breast size,
tumor location and the glandular density, in addition to the resid-
ual tumor volume [5]. Response to therapy, however, still plays a
role in the decision for BC, resulting in a selection bias when com-
paring our BC group to the mastectomy group.
The third and most important aspect is the local recurrence rate.
Different studies have reported local recurrence rates with BC after
NT; however, in most studies, the proportion of T3 tumors was small.
Additionally the results are not easily comparable because of dif-
ferences in criteria for NT and for breast conservation after treatment
and because of inconsistencies in the reporting of receptor status.
Furthermore in some studies the local recurrence rates are re-
ported jointly for BCT and mastectomy. In Table 3 we have
extrapolated the T3 relevant results from the different studies and
added our own results for comparison.
Our study has a few limitations. First, it is a retrospective anal-
ysis of a prospectively collected database; second, an ideal
comparison would have been with the subgroup of patients who
were BC candidates but still electedmastectomy; however, this group
was not identiﬁed separately.
Following is a short review of previously published data. Touboul
et al. [10] reported a 20% 10-year local failure rate in 47 selected
patients with residual tumors <3 cm following combination of NT
and radiation that were treated with BC. In a series by Mauriac et al.
[12], no preoperative radiation was given, and a different cutoff treat-
ment was tailored according to the response to NT; NT was followed
by radiation alone for complete responders, BC for residual tumors
≤2 cm and completion mastectomy for residual tumors > 2 cm. Forty
patients underwent BC surgery, with a 23% local failure rate at 124
months of follow-up.
In the subgroup of patients who were downstaged to BC fol-
lowing NT in the NSABP 18 trial [3], the local failure rate was 7%
in patients who were eligible for BC before therapy vs. 15% in those
who were downstaged to BC by NT. In a study from Institute Curie
[12], the reported rate of local failure was 16% and 21.5% at 5 and
10 years, respectively, and only 10% of patients had T3 disease.
A number of trials have reported a low local failure rate in BC
following NT. In a study by Bonadonna et al. [11], patients eligible
for mastectomy were treated by NT, and BC was performed in 63%,
in which 11% were T3. The overall local failure rate was 6.8% and
only 4.3% in the T3 subset. In a surgery outcome analysis of the NOAH
trial [18], which was restricted to HER2 positive patients treated
with chemotherapy and trastuzumab, no local failure was found in
patients who underwent BC during a mean follow-up of 3.5 years.
The rate of BC was low since BC was recommended mainly for
tumors <4 cm at presentation or upon patient’s request in larger
tumors if an objective response to NT was achieved; only16%
of tumors larger than 5 cm underwent BC. Five percent local failure
rate was reported in the M.D. Anderson series of BC following NT
[15], including all T stages and without speciﬁcs regarding eligi-
bility for breast conservation prior to NT. In the NSABP 18 study
analysis [3], patients who were not eligible for BC prior to NT fared
worse in terms of local failure rates compared to patients who were
eligible to BC upfront.
The extent of imaging required prior to embarking on an attempt
at BC after NT is also a matter of controversy. Clearly, MRI could add
information regarding the residual tumor extent, and we ordered
it when possible; in 10/30 patients MRI was performed, and in 20/
30 patients only a repeat mammography and ultrasound was
performed.
In our series all patients underwent an operation with the goal
of removing the entire tumor with negative margins. In addition,
radiation therapy was mandated for all patients and was thus ad-
ministered, except to one non-compliant patient and one
nonagenarian. Only patients with tumor on the inked margins were
recommended to have a re-excision. Size in centimeters was mea-
sured on presentation by imaging; all patients were downstaged
for BC by NT and we had no cutoff size for BC. We can conclude that
at a mean follow-up of 43 months, BC is a safe option for tumors
Table 3
Studies including BCT for T3 patients following neoadjuvant chemotherapy.
Authors Trial Follow-up months BCT T3 Selection criteria Local failure Distal failure
Touboul et al. (1997) [10] Prospective 82 95 51 (53%) Residual tumor <3 cm 20% 24%
Bonadonna et al. (1998) [11] Prospective 96 455 52 (11%) If tumor suﬃciently reduced in size 4.3%a –
Fisher et al. (1998) [3] Prospective 60 450 96 (13%)b Not speciﬁed 7.9% –
Mauriac et al. (1999) [12] Prospective 124 84 29 (22%)b Residual tumor <2 cm 31% 45%
Rouzier et al. (2001) [13] Retrospective 60 257 23 (10.1%) Residual tumor <3 cm 16% 34.1%
Kuerer et al. (2001)[14] Retrospective 53 109 27 (25%) Not speciﬁed 5% 11%
Chen et al. (2004) [15] Retrospective 60 340 83 (24%) Not speciﬁed 5% 13%
Rouzier et al. (2004) [16] Retrospective 60 287 52 (18%) Residual tumor <3 cm 10% 25%
Mamounas et al. (2012) [17] Prospective 120 1890 776 (25%)b Not speciﬁed 10% –
Libson et al. (2015) Retrospective 43 30 30 (100%)c Surgical feasibility 0 13.3%
a Failure rate for T3 patients alone.
b T3 rate included patients who underwent BC + mastectomy.
c Including 5 cm tumors.
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≥5 cm downstaged by NT, when pathological margins are negative
and radiation is administered.
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